In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion Pharmaceuticals Inc.

www.alexionpharma.com

Latest From Alexion Pharmaceuticals Inc.

Alexion Buys A Complementary Business With Achillion

The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.

Interview: Akari's Coversin Ticking Along Nicely

The C5 complement inhibitor class is in the news following UCB's bid for Ra Pharmaceuticals. Akari's CEO tells Scrip he thinks Coversin, which inhibits leukotriene B4 as well as C5, may offer more benefits in certain orphan diseases.

Rare Diseases Inflammation

Deal Watch: GSK Furthers Cancer Gene Therapy Plans Via Lyell Collaboration

GSK hopes the San Francisco biotech’s technology can help its cell therapy pipeline address solid tumors. Avacta partners with ADC on antibody-drug conjugates.

Deals Business Strategies

Roche Takes Orphan Satralizumab To EMA

There are six new entries on the latest list of products under review at the European Medicines Agency – products with orphan status from Roche and Novo Nordisk and four generic or biosimilars.

Europe Drug Review
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register